Vol 2011, No 3 (2011)

Table of Contents

Research & Development

Lycera and Merck & Co. to Develop Autoimmune Disease Drugs Targeting Th17 Cells Abstract
Heather Cartwright
Epizyme Signs its Second Major Deal of 2011 Abstract
Heather Cartwright

Licensing

Astellas Gains Ex-Asia Rights to Tivozanib from AVEO in Potential US$1.4 B Deal Abstract
Heather Cartwright
Cell Therapeutics Expands its Late-Stage Oncology Pipeline with Chroma Therapeutics’ Tosedostat Abstract
Heather Cartwright

Mergers & Acquisitions

Genzyme Finally Agrees to US$20.1 B Plus CVR Takeover by Sanofi-aventis Abstract
Heather Cartwright
Gilead Continues its Diversification Strategy with Acquisition of Calistoga Pharmaceuticals Abstract
Heather Cartwright
Forest Laboratories Agrees to Acquire Clinical Data for US$1.2 B Upfront Abstract
Heather Cartwright
Kyowa Hakko Kirin Makes Takeover Bid for ProStrakan to Expand in Foreign Markets Abstract
Heather Cartwright
Daiichi Sankyo Targets US Oncology Market with US$935 M Plexxikon Acquisition Abstract
Heather Cartwright


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.